Background {#Sec1}
==========

Vitamin D has receptors that are expressed in many nucleated cells and controls the expression of various human genes \[[@CR1]\]. Vitamin D deficiency aggravates bone diseases, leading to osteoporosis, and increases the risk of falls and fractures \[[@CR2], [@CR3]\]. In addition to its relationship with skeletal health, the association of vitamin D deficiency and various other diseases such as hypertension \[[@CR4]\], cardiovascular disease \[[@CR5]--[@CR7]\], cancer \[[@CR8]--[@CR11]\], infectious disease, and metabolic disease \[[@CR12]\] have also received attention. Vitamin D deficiency is a global health problem related to poor nutrition \[[@CR2]\], and the prevalence of vitamin D deficiency is relatively high worldwide. According to data from the National Health and Nutrition Examination Survey of the United States, 10--40% of the population is deficient in vitamin D \[[@CR13]\]. The prevalence of vitamin D deficiency is even higher among Asians than in the United States \[[@CR2]\]. According to a Korean report, 47.3% of males and 64.5% of females are deficient in vitamin D \[[@CR14]\]. Correcting vitamin D deficiency is essential to preventing several related diseases and improving global human health.

Hematuria is the presence of red blood cells in the urine. The prevalence of hematuria ranges from 0.2 to 16.1% in the general population \[[@CR15], [@CR16]\]. In one study, 6.2% of Korean participants who underwent health screening had asymptomatic hematuria \[[@CR17]\]. Hematuria is frequently the result of nonglomerular causes, such as an infection or stone in the urinary tract. Additionally, hematuria can be a manifestation of glomerular kidney disease or polycystic kidney disease and is known to be a risk factor of progressive kidney dysfunction and end-stage renal disease \[[@CR18]\]. Various urinary tract neoplasms originating in the bladder, prostate, ureter, and kidney may manifest as microscopic and gross hematuria \[[@CR19]\]. Therefore, hematuria is an important sign of disease and its cause should be evaluated to prevent further disease progression.

Despite the clinical importance of vitamin D deficiency and hematuria, no studies have been conducted to investigate their correlation in the general population. Correlation between proteinuria and vitamin D deficiency has been evaluated in various studies \[[@CR20], [@CR21]\]. However, the association between vitamin D status and the hematuria, another important parameter of kidney disease other than proteinuria, has not been evaluated yet. Furthermore, there are accumulating evidence that vitamin D deficiency contributes to pathologic conditions that can be presented as hematuria such as urinary stone \[[@CR22]\], infection \[[@CR23]\] and malignancy \[[@CR24]\]. The present study is the first to examine this correlation using data of a nationwide population-based survey, stratified by sex and menopause status as these parameters are known to be important in analyzing the effects of vitamin D deficiency \[[@CR25], [@CR26]\].

Methods {#Sec2}
=======

Study population {#Sec3}
----------------

This was a nationwide population-based cross-sectional study using data of the Korean National Health and Nutrition Examination Survey (KNHANES), conducted by the Korean Centers for Disease Control and Prevention in South Korea. We used data of both the KNHANES V (2010--2012) and KNHANES VI (2013--2015) surveys conducted in South Korea. Of a total 41,102 participants, we included 20,295 participants, aged ≥18 years, for whom results of both urinalysis and serum 25-hydroxyvitamin D (25(OH)D) levels were available. After excluding 55 women who were menstruating at the time of examination, a total 20,240 participants (49.2% of the total population surveyed) were analyzed in the present study.

Study variables {#Sec4}
---------------

Demographic variables were collected during health interviews, including age, sex, menopause status, alcohol consumption, and smoking status. Alcohol consumption was defined as drinking once or more per month. Smoking status was classified as nonsmoker, former smoker, or current smoker. Information was also obtained about underlying comorbidities including hypertension, diabetes, and cardiovascular disease. Weight (kg) and height (cm) were measured with participants wearing a gown and no shoes. Body mass index was calculated as weight (kg) divided by square of height (m^2^). Body mass index \< 18.5 kg/m^2^, 18.5--22.9 kg/m^2^, 23.0--24.9 kg/m^2^, and ≥ 25.0 kg/m^2^ were defined as underweight, normal weight, overweight, and pre-obese and obesity, respectively \[[@CR27]\]. Blood pressure was measured with patients at rest. Participants were defined as having hypertension with systolic blood pressure ≥ 140 mmHg, diastolic blood pressure ≥ 90 mmHg, or a history of taking blood pressure lowering agents. Fasting blood samples were collected during health examination surveys. The samples were refrigerated and transported to the designated central laboratory (NeoDin Medical Institute, Seoul, Korea). Fasting glucose levels were measured using the enzymatic UV (hexokinase) method with a Hitachi 7600 automated analyzer (Hitachi, Tokyo, Japan). Participants with diabetes were defined as those with a fasting glucose level of ≥126 mg/dL or taking diabetes medication or insulin. A fasting glucose level between 100 mg/dL and 125 mg/dL was defined as impaired fasting glucose status. Hypercholesterolemia was defined in participants with total fasting cholesterol level ≥ 240 mg/dL or taking cholesterol lowering agents. Total cholesterol was measured using an enzymatic method and a Hitachi 7600--210 analyzer (Hitachi). Serum hemoglobin levels were measured using the SLS hemoglobin detection method with a XE-2100D analyzer (Sysmex, Tokyo, Japan), and anemia was defined as a hemoglobin level \<  13 g/dL for men and \< 12 g/dL for women. Serum creatinine levels were measured by the Jaffe rate-blanked and compensated method using the Hitachi 7600--210 analyzer. The estimated glomerular filtration rate was calculated using the Chronic Kidney Disease Epidemiology Collaboration equation \[[@CR28]\]. Serum 25(OH)D levels were measured using radioimmunoassay with a 1470 WIZARD gamma counter (PerkinElmer Finland Oy, Finland) with a 25-hydroxyvitamin D 125I RIA kit (DiaSorin Corp., Stillwater Minnesota, USA). We defined serum 25(OH)D inadequacy as serum 25(OH)D level \<  30 ng/mL and deficiency as \< 20 ng/mL \[[@CR29]\]. Random early morning urine samples were collected, whenever possible. All urine samples were refrigerated and transported to the central laboratory (NeoDin Medical Institute). The results of dipstick tests were scored from negative to + 4. Hematuria, proteinuria, and glycosuria were defined as ≥1+ on a dipstick test.

Statistical analysis {#Sec5}
--------------------

IBM SPSS version 20.0 (IBM Corp., Armonk, NY, USA) was used for all analyses. Continuous variables including age, height, body mass index, blood pressure, fasting blood glucose, serum hemoglobin, and estimated glomerular filtration rate showed normal distributions and were presented as mean value and standard deviation. However, serum 25(OH)D levels showed a non-normal distribution, and were therefore expressed as median value and interquartile range. A logistic regression analysis was used to calculate odds ratios (ORs) and 95% confidence intervals for the risk of hematuria. Multivariate logistic regression was conducted after adjusting all covariates, such as comorbidities and laboratory findings. A nonlinear relationship between 25(OH)D and risk of hematuria was examined using the cubic spline regression model. A *P* value \< 0.05 was considered significant.

In this study, subsequent analyses according to sex and menopausal status were conducted to see the risk difference in hematuria. Predicted probability plot of hematuria was drawn according to sex using cubic spine regression model and multivariate logistic regression was conducted according to sex and menopausal status in women.

Results {#Sec6}
=======

Baseline characteristics {#Sec7}
------------------------

Of a total 20,240 study participants, 10,847 (53.6%) were women and 5388 (26.6%) were identified as postmenopausal. The mean participant age was 49 ± 16.3 years and mean estimated glomerular filtration rate was 88 ± 17.4 mL/min/1.73 m^2^. There were a total 3144 (15.5%) participants with hematuria, and the mean serum 25(OH)D level was 17.4 ± 6.2 ng/mL (median 16.6 ng/mL (13.1--20.8 ng/mL)). Among the total participants, 19,427 (96.0%) had serum 25(OH)D levels \< 30 ng/mL, and 14,373 (71.0%) had levels below 20 ng/mL. Blood pressure corresponded to prehypertension in 4845 (23.9%) participants, and 6137 (30.3%) participants had hypertension. A total 3751 (18.5%) patients were diagnosed as having impaired fasting glucose and 1969 (9.7%) patients had diabetes mellitus. A total 503 (2.5%) participants showed glycosuria and 228 (1.1%) proteinuria. Other demographic and laboratory findings are shown in Table [1](#Tab1){ref-type="table"}.Table 1Baseline characteristics of the study populationTotal (*n* = 20,240)Normal (≥ 30 ng/mL) (*n* = 813)Inadequacy (\<  30 ng/mL) (*n* = 19,427)*P*Age (years)49.4 ± 16.357.9 ± 14.149.1 ± 16.3\<  0.001Female (%)53.646.653.9\<  0.001Post-menopausal women (%)26.626.236.9\<  0.001Body mass index (kg/m^2^)23.7 ± 3.423.4 ± 3.123.7 ± 3.40. 006Obesity classification (%)0.026 Under weight4.13.44.1 Normal weight39.141.439.0 Over weight24.026.723.9 Obesity32.828.433.0 Alcohol (%)72.868.273.00.003Smoking (%)0.010 None57.953.058.1 Former smoker20.524.120.3 Current smoker21.622.921.6 Systolic blood pressure (mmHg)119.6 ± 17.1123.3 ± 17.5119.4 ± 17.1\<  0.001 Diastolic blood pressure (mmHg)76.2 ± 10.576.9 ± 10.376.2 ± 10.50.066Blood pressure status (%)\<  0.001 Prehypertension2527.324.9 Hypertension31.741.231.3 Fasting blood glucose (mg/dL)98.1 ± 21.799.7 ± 19.698.0 ± 21.80.016Impaired glucose tolerance (%)\<  0.001 Impaired fasting glucose19.719.622.7 Diabetes mellitus10.410.213.4 Cardiovascular disease (%)2.63.72.50.063 Hypercholesterolemia (%)15.017.314.90.071 Hemoglobin (g/dL)14.1 ± 1.614.1 ± 1.514.1 ± 1.60.511 Anemia (%)8.09.27.90.229 Estimated GFR (mL/min/1.73 m^2^)94.7 ± 17.283.7 ± 17.788.6 ± 17.3\<  0.001 Estimated GFR under 60 mL/min/1.73 m^2^ (%)3.77.33.6\<  0.001 Serum 25(OH)D (ng/mL)^a^16.6 (13.1--20.8)33.1 (31.4--35.7)16.3 (12.9--20.2)\<  0.001 Glycosuria (%)2.52.12.50.534 Proteinuria (%)1.10.61.10.215 Hematuria (%)15.512.315.70.011*GFR* glomerular filtration rate, *25(OH)D* 25-hydroxyvitamin D^a^Data are expressed as the median (interquartile range) when the data distribution was skewed

Factors associated with hematuria {#Sec8}
---------------------------------

A univariate logistic regression analysis was conducted to examine the association between the covariates and hematuria (Table [2](#Tab2){ref-type="table"}). Age \> 30 years, female sex and especially postmenopausal status, hypertension, hypercholesterolemia, anemia, 30--60 mL/min/1.73 m^2^ of estimated glomerular filtration rate, and proteinuria were associated with risk of hematuria. Drinking alcohol, former or current smoker, diabetes mellitus, and glycosuria showed a negative relationship with hematuria. These covariates were adjusted in subsequent multivariate regression analyses.Table 2Odds ratios for hematuria of baseline variablesVariablesOR (95% CI)*P*Age (years) \<  201 (reference) 20--291.14 (0.780--1.651)0.508 30--391.51 (1.054--2.166)0.025 40--492.21 (1.550--3.162)\<  0.001 50--592.53 (1.776--3.605)\<  0.001 60--692.62 (1.835--3.732)\<  0.001 ≥ 703.72 (2.604--5.314)\<  0.001Gender Male1 (reference) Female2.60 (2.390--2.825)\<  0.001Menopausal status Pre-menopause1 (reference) Post-menopause3.06 (2.782--3.356)\<  0.001Body mass index (kg/m^2^) \<  18.51 (reference) 18.5--22.91.04 (0.857--1.271)0.673 23.0--24.90.94 (0.769--1.157)0.573 **≥** 25.00.94 (0.771--1.149)0.551Alcohol (−)1 (reference) (+)0.68 (0.629--0.742)\<  0.001Smoking None1 (reference) Former smoker0.53 (0.470--0.587)\<  0.001 Current smoker0.62 (0.561--0.689)\<  0.001Hypertension None1 (reference) Prehypertension0.91 (0.910--1.111)0.913 Hypertension1.20 (1.096--1.311)\<  0.001Diabetes mellitus None1 (reference) Impaired fasting glucose1.10 (0.996--1.209)0.061 Diabetes mellitus0.67 (0.579--0.777)\<  0.001Cardiovascular disease (−)1 (reference) (+)1.19 (0.944--1.499)0.141Hypercholesterolemia (−)1 (reference) (+)1.13 (1.020--1.261)0.020Anemia (−)1 (reference) (+)1.57 (1.384--1.778)\<  0.001Estimated GFR (mL/min/1.73 m^2^) **≥** 60.01 (reference) 30.0--59.91.35 (1.117--1.627)0.002 \<  30.01.55 (0.739--3.248)0.247Glycosuria (−) or trace1 (reference) **≥** 1+0.62 (0.465--0.829)\<  0.001Proteinuria (−) or trace1 (reference) **≥** 1+5.12 (3.940--6.663)\<  0.001*OR* odds ratio, *CI* confidence interval, *GFR* glomerular filtration rate

Association between serum vitamin D level and hematuria {#Sec9}
-------------------------------------------------------

As shown in Fig. [1](#Fig1){ref-type="fig"}, the prevalence of hematuria increased in proportion to lower 25(OH)D levels. A total 13.8% of participants in the 4th quartile of serum 25(OH)D (≥ 20.8 ng/mL) showed hematuria whereas the prevalence of hematuria increased from the 3rd to 1st quartiles, as follows: 14.6% in the 3rd quartile (16.4--20.7 ng/mL), 16.3% in the 2nd quartile (13.0--16.3 ng/mL), and 17.7% in the 1st quartile (\< 13.0 ng/mL) (*P*~trend~ \<  0.001). In univariate analysis, the 3rd and 4th quartiles showed a higher risk of hematuria than the 1st quartile: OR 1.20 (1.072--1.336) and OR 1.35 (1.210--1.501) in the 3rd and the 4th quartiles, respectively. When comparing the groups with 25(OH)D levels \< 30 ng/mL and ≥ 30 ng/mL, the lower group showed a higher OR of hematuria (1.33 (1.071--1.639)) than the higher group (*P* = 0.010). When vitamin D deficiency was defined as \< 20 ng/mL, the deficient group showed a higher OR of hematuria (1.20 (1.102--1.309)) than the higher group (*P* \<  0.001). These differences were also significant despite adjusting for multiple covariates which were significant in the univariate analysis (Table [3](#Tab3){ref-type="table"}).Fig. 1Prevalence of hematuria according to serum 25-hydroxyvitamin D levelTable 3Odds ratios for hematuria according to serum 25-hydroxyvitamin D levelsGroupsUnivariateMultivariate^a^OR (95% CI)*P*OR (95% CI)*P*Quartiles 1st quartile (≥ 20.8 ng/mL)1 (reference)1 (reference) 2nd quartile (16.4--20.7 ng/mL)1.07 (0.960--1.196)0.2191.14 (1.014--1.284)0.028 3rd quartile (13.0--16.3 ng/mL)1.20 (1.072--1.336)0.0011.26 (1.114--1.415)\<  0.001 4th quartile (\<  13.0 ng/mL)1.35 (1.210--1.501)\<  0.0011.40 (1.240--1.572)\<  0.001Vitamin D inadequacy Normal (≥ 30 ng/mL)1 (reference)1 (reference) Inadequacy (\<  30 ng/mL)1.33 (1.071--1.639)0.0101.44 (1.150--1.800)0.001Vitamin D deficiency Normal (≥ 20 ng/mL)1 (reference)1 (reference) Deficiency (\<  20 ng/mL)1.20 (1.102--1.309)\<  0.0011.25 (1.137--1.373)\<  0.001^a^Adjusted for age, gender, alcohol, smoking, diabetes, hypertension, hypercholesterolemia, anemia, chronic kidney disease, glycosuria, and proteinuria

Subgroup analysis according to sex and menopausal status {#Sec10}
--------------------------------------------------------

Because the risk of several diseases differs according to sex and menopausal status \[[@CR10], [@CR25], [@CR30]\], subsequent analyses were conducted after stratification by these factors. Figure [2](#Fig2){ref-type="fig"} shows the predicted probability plot of hematuria according to sex. The linear relationship seemed to be more dominant in women than in men. When multiple covariates were adjusted, the low 25(OH)D groups (inadequate or deficient) showed higher ORs of hematuria than the high 25(OH)D groups for both sexes. According to menopausal status, no relationship was found among premenopausal women, however, the relationship was significant in postmenopausal women (Table [4](#Tab4){ref-type="table"}).Fig. 2Nonlinear relationship between serum 25-hydroxyvitamin D and risk of hematuria in male (**a**) and female (**b**) subjectsTable 4Risk of hematuria after stratification by sex and menopausal statusMaleFemalePre-menopausal femalesPost-menopausal femalesOR (95% CI)^a^*P*OR (95% CI)^a^*P*OR (95% CI)^a^*P*OR (95% CI)^a^*P*Quartiles 1st quartile1 (reference)1 (reference)1 (reference)1 (reference) 2nd quartile1.23 (1.014--1.498)0.0361.09 (0.941--1.266)0.2470.94 (0.726--1.225)0.6591.18 (0.986--1.418)0.071 3rd quartile1.38 (1.121--1.706)0.0021.20 (1.035--1.386)0.0151.12 (0.875--1.433)0.3691.19 (0.991--1.437)0.062 4th quartile1.35 (1.080--1.695)0.0071.38 (1.200--1.593)\<  0.0011.15 (0.905--1.460)0.2531.58 (1.320--1.892)\<  0.001Vitamin D inadequacy Normal1 (reference)1 (reference)1 (reference)1 (reference) Inadequacy1.32 (0.915--1.889)0.1391.50 (1.127--1.989)0.0051.10 (0.597--2.019)0.7641.62 (1.177--2.237)0.003Vitamin D deficiency Normal1 (reference)1 (reference)1 (reference)1 (reference) Deficiency1.26 (1.077--1.481)0.0041.24 (1.101--1.393)\<  0.0011.15 (0.933--1.419)0.1881.29 (1.123--1.491)\<  0.001*OR* odds ratio, *CI* confidence interval^a^Adjusted for age, alcohol, smoking, diabetes, hypertension, hypercholesterolemia, anemia, chronic kidney disease, glycosuria, and proteinuria

Discussion {#Sec11}
==========

Vitamin D deficiency and hematuria are important public health problems with high incidence in the general population, and both may be related to more severe diseases. However, there have been no studies conducted to investigate the relationship between vitamin D deficiency and hematuria. We addressed this question in the present study, using data of the KNHANES nationwide population-based survey. The risk of hematuria increased with decreased serum 25(OH)D levels. This increasing risk of hematuria was seen for both vitamin D inadequacy and deficiency, particularly in postmenopausal women. Nevertheless, this relationship was only significant after menopause in women.

Previous studies have reported the correlations between vitamin D deficiency and various diseases wherein hematuria is one of the disease signs \[[@CR22], [@CR24], [@CR31], [@CR32]\]. Because vitamin D enhances the absorption of calcium from the intestine and stimulates bone absorption to physiologically increase serum calcium levels \[[@CR2]\], it is plausible that vitamin D might increase the risk of urinary stones, thereby leading to hematuria. However, the evidence is insufficient owing to the observational nature of conducted studies \[[@CR33], [@CR34]\], and there are contradictory reports in which the risk of calcium-based urinary stones is higher with vitamin D deficiency \[[@CR22], [@CR35]\].

Vitamin D has an important role in the immune system via controlling the expression of many immunologic factors. As a result, an association between vitamin D deficiency and risk of urinary tract infection has been reported \[[@CR23], [@CR36], [@CR37]\]. One study showed that premenopausal women had a 4-fold increased risk of recurrent urinary tract infection with serum 25(OH)D levels \< 15 ng/mL \[[@CR23]\], and the correlation between vitamin D deficiency and urinary tract infection has been documented in children and kidney transplant recipients \[[@CR36], [@CR37]\]. Because hematuria is one sign of urinary tract infection, the present results may be attributable to the above mechanism.

Vitamin D deficiency is related to the progression of kidney disease via both direct and indirect effects. End-stage renal disease and proteinuria are more prevalent in individuals who are deficient in vitamin D \[[@CR20], [@CR21], [@CR38]\]. In a cross-sectional analysis of patients with polycystic kidney disease, kidney volumes were larger in individuals with vitamin D deficiency \[[@CR31]\]. Animal studies have showed that low vitamin D levels are correlated with podocyte loss and development of glomerulosclerosis \[[@CR39]\]. An acute kidney injury model demonstrated that vitamin D deficiency induces tubulointerstitial damage and fibrosis and diminishes renal vascularity, which finally leads to chronic change \[[@CR40]\]. Vitamin D deficiency is additionally linked to activation of the renin--angiotensin system, promoting endothelial damage and the progression of diabetes \[[@CR41]\].

Vitamin D deficiency is related to high incidence and aggressiveness of various malignancies \[[@CR8], [@CR10], [@CR42]\] that have been documented in the urological system, such as renal cell carcinoma \[[@CR24]\] and bladder cancer \[[@CR32]\]. Various possible antineoplastic mechanisms of active vitamin D have been suggested. Active vitamin D can regulate transcription of anticancer target genes that induce apoptosis and differentiation and inhibit proliferation, inflammation, angiogenesis, invasion, and metastasis of cancer cells \[[@CR43]\]. Vitamin D regulates signaling pathways such as the Wnt/β-catenin, estrogen receptor, and androgen receptor in the colon, breast, and prostate, respectively, which subsequently affect the growth of cancer in each tissue \[[@CR43]\]. Additionally, microRNA can mediate the antineoplastic functions of vitamin D \[[@CR43]\]. Collectively, the above mechanisms support the present study results.

The subsequent analysis showed that the correlation between hematuria and vitamin D deficiency was predominant in postmenopausal women but not in premenopausal women. The different effects of vitamin D deficiency according to menopausal status have been previously reported \[[@CR10], [@CR26], [@CR30]\], but the mechanisms have not been clearly determined. Vitamin D is one of the steroid hormones and it is closely related to sex hormones such as estrogen and testosterone, levels of which may vary with menopausal status, thereby affecting the relationship with disease risk. Further fundamental studies are needed to confirm the different effects of vitamin D on hematuria according to menopausal status.

This study has several limitations. We used one-time spot urine samples and defined presence of hematuria as ≥1+ on a dipstick test. Owing to the possibility of a false positive or false negative on a single test, this approach might have resulted in incorrectly grouped participants. Furthermore, positive dipstick test does not always mean hematuria but may reflect the presence of heme pigment which can be positive in the condition of red blood cell lysis or myositis. Accordingly, using the dipstick test alone may result in false-positivity. Another major limitation is that, we could not obtain information on the cause of hematuria and other laboratory results (e.g., calcium, phosphorous, parathyroid hormone and 1,25 OH Vitamin D level) which may have an interaction in the relationship results. Because the study design was cross-sectional, there is a lack of information about whether the effects of vitamin D deficiency on hematuria eventually lead to occurrence of disease and alter patient prognosis.

Our study is the first to address the correlation between vitamin D deficiency and hematuria risk using a large nationwide cohort. Despite adjusting for several covariates that might affect the presence of hematuria, participants who had inadequate or deficient vitamin D levels had a higher risk of hematuria than participants with normal levels. Further physiological and epidemiological studies are required to find out the underlying mechanisms and whether the supplemental vitamin D would be beneficial in various diseases related to hematuria.

Conclusions {#Sec12}
===========

Vitamin D deficiency and hematuria are both common health problem in general population. The association between vitamin D deficiency and hematuria was noticed in this study, particularly in postmenopausal women. Patients with vitamin D deficiency should be concern about the risk of hematuria and related disease.

25(OH)D

:   Serum 25-hydroxyvitamin D

KNHANES

:   Korean National Health and Nutrition Examination Survey

OR

:   Odds ratio

None.

Funding {#FPar1}
=======

None.

Availability of data and materials {#FPar2}
==================================

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

HJR designed the study, collected, analyzed and interpreted the data, and drafted the manuscript. HJC and YKO collected data, interpreted data and reviewed the manuscript. KWJ, YSK, and CA contributed to conception and design of the study, and interpretation of data. SSH designed the study, performed the experiments, interpreted the data and reviewed the final manuscript. All authors read and approved the manuscript.

This study was conducted in accordance with the Declaration of Helsinki. The KNHANES was approved by the institutional review board at the Korea Center for Disease Control and Prevention (nos. 2010-02CON-21-C; 2011-02CON-06-C; 2012-01EXP-01-2C; 2013-07CON-03-4C; 2013-12EXP-03-5C; and 2015-01-02-6C) from 2010 to 2015. All the data collection and surveys were conducted with the participant's written consent.

Not applicable.

The authors declare that they have no competing interests.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
